You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
First‐in‐man allopregnanolone use in super‐refractory status epilepticus
Contributor:
Vaitkevicius, Henrikas;
Husain, Aatif M.;
Rosenthal, Eric S.;
Rosand, Jonathan;
Bobb, Wendell;
Reddy, Kiran;
Rogawski, Michael A.;
Cole, Andrew J.
Published:
Wiley, 2017
Published in:
Annals of Clinical and Translational Neurology, 4 (2017) 6, Seite 411-414
Description:
<jats:title>Abstract</jats:title><jats:p>Super‐refractory status epilepticus (<jats:styled-content style="fixed-case">SRSE</jats:styled-content>) is associated with high morbidity and mortality. Treatment of <jats:styled-content style="fixed-case">SRSE</jats:styled-content> is complicated by progressive cortical hyperexcitability believed to result in part from synaptic <jats:styled-content style="fixed-case">GABA</jats:styled-content> receptor internalization and desensitization. Allopregnanolone, a neurosteroid that positively modulates synaptic and extrasynaptic <jats:styled-content style="fixed-case">GABA<jats:sub>A</jats:sub></jats:styled-content> receptors, has been proposed as a novel treatment. We describe the first two patients with <jats:styled-content style="fixed-case">SRSE</jats:styled-content> who were each successfully treated with a 120‐h continuous infusion of allopregnanolone. Both patients recovered from prolonged <jats:styled-content style="fixed-case">SRSE</jats:styled-content> with good cognitive outcomes.</jats:p>